A test batch of favipiravir will appear on the Russian market in a week. This drug has shown good results in studies among patients with coronavirus infection.
“We are a group Chemrar invest in a drug that has shown very good results in China, and a test batch will be a week” – leads TASS words of the head of the Russian direct investment Fund (RDIF) Kirill Dmitriev.
According to RDIF, the head of the Chinese national center of biotechnology Zhang Xinmin said that the effectiveness of favipiravir against coronavirus confirmed by clinical trials conducted in the cities of Wuhan and Shenzhen. The drug showed a decrease in time during which the coronavirus remains in the body of patients, from 11 to four days. Also, according to Zhang, the marked improvement of the affected lung in 91% of patients compared to 62% of control patients not receiving the drug.
Dmitriev also said that the planned further investments in the drugs against the coronavirus. “Planned investments in enterprises that produce ventilation machines and other medical equipment. And even think about online education, such as planned investment in the company Teach.ru. We are looking at where we can be useful in various industries related to the fight against coronavirus,” – said the head of RDIF.
Earlier the Supervisory Council of the Russian direct investment Fund (RDIF) approved the creation of a joint venture (JV) with a group of companies “Chemrar” for the production of favipiravir and other sorts of innovative medicines, including based on it.